Short answer
Merck & Co. (MRK) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $16.3B (up 4.9% year over year) with net income of −$4.2B.
Q1 2026 key financials · XBRL
- Revenue
- $16.3B
- +4.9% YoY
- Net income
- −$4.2B
- −183.5% YoY
- EPS (diluted)
- −$1.72
- −185.6% YoY
Source: XBRL data from the Merck & Co. (MRK) Q1 2026 10-Q on SEC EDGAR. USD.
Merck & Co. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $16.286B, up 5% YoY from $15.529B; U.S. sales $9.164B, up 8%
- Oncology strongest disclosed franchise; Keytruda sales $8.034B, up 12% from $7.205B
- Vaccines weakest disclosed franchise; Gardasil/Gardasil 9 sales $1.069B, down 19% from $1.327B
- Cidara acquisition drove $9.0B R&D charge, or $3.62 per share, in Q1 2026
- Pricing pressure and IRA actions expected to continue negatively affecting sales and profits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Merck & Co. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.